G Paintaud reports grants from Chugai, Shire/Takeda, Amgen, Merck, Lilly, Novartis, Roche Pharma, Genzyme/Sanofi. T Lecomte reports consulting honorarium for Sanofi, Bayer and Servier and educational presentations for Eli Lilly and Servier. EA7501 and EA4245 are implicated in the program ‘Investissements d’avenir’ LabEx MAbImprove, grant agreement ANR-10-LABX-53 (French National Research Agency). This project was supported by grants on behalf of the following French department committees of Ligue Contre le Cancer Grand-Ouest: 16 (Charente), 37 (Indre-et-Loire), 49 (Maine-et-Loire) and 72 (Sarthe). M Guéguinou is a recipient of a 3-year postdoctoral grant from Région Centre – Val de Loire. R Chautard was a recipient of a one-year fellowship grant ‘année recherche’ from CHRU Tours. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.